Bedrijfsoverzicht
BriaCell Therapeutics Corp. is a pre-clinical stage immuno-oncology entity dedicated to developing targeted immunotherapies designed to transform cancer care protocols. The company operates within the Healthcare sector and specifically functions in the Biotechnology industry, where it focuses on advancing novel treatments for end-stage breast cancer. Its market capitalization stands at $31.03M, while its annual revenue is not available, and the employee count is listed as N/A. These financial figures indicate that the company operates as a micro-cap biotechnology firm in the early stages of development, characterized by a lack of established commercial revenue streams and a small operational footprint relative to large-cap pharmaceutical peers. The absence of reported revenue and employee data underscores the typical characteristics of pre-clinical stage companies that prioritize research and development expenditures over immediate commercialization and workforce expansion.
Financiële gezondheid
The company reports a Net Income of $-29,637,656 and an EBITDA of $-30,630,110 for the trailing twelve months, with Revenue and Price to Sales metrics listed as N/A. The significant gap between the reported revenue (which is unavailable) and the substantial net income losses reveals a cost structure dominated by high research and development expenses typical of early-stage biotechnology firms. Free Cash Flow stands at $-20,493,214, indicating that the company is burning cash rapidly to fund its clinical trial programs and operational activities. This negative cash flow position suggests limited financial flexibility in the short term, relying heavily on external capital markets for funding rather than organic cash generation. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which indicates that the company has not yet achieved commercial profitability or that revenue figures are insufficient to calculate meaningful margins in the absence of sales data. On the balance sheet, the company holds $29.90M in cash against $0 in debt, resulting in a Debt to Equity ratio that is N/A. This cash position relative to zero debt suggests a conservative balance sheet structure, although the lack of revenue limits the ability to service debt if it were to accrue. The Current Ratio is 10.10, which indicates a robust short-term liquidity position given the absence of current liabilities, providing a substantial buffer to meet immediate financial obligations. Return on Equity is -179.2% and Return on Assets is -89.4%, metrics that reveal that management effectiveness is currently measured by the rate of capital consumption rather than profit generation, as the company is still in the investment phase of its lifecycle.
Waarderingsbeoordeling
The Trailing P/E Ratio (TTM) is N/A and the Forward P/E is -10.97, a disparity that implies earnings are negative and traditional valuation multiples based on profitability are not applicable for this pre-revenue company. The Price to Book ratio is 1.00, indicating that the market values the company at exactly its net asset value, suggesting no significant market premium over the book value of its equity. The Price to Sales ratio is N/A and the EV/EBITDA is -0.01, meaning these alternative valuation metrics cannot provide a standard comparison against profitable peers but highlight the company's reliance on asset backing rather than cash flow multiples. The stock has a 52-Week High of $98.20 and a 52-Week Low of $3.60, placing the current trading price significantly below the 52-week high and reflecting the high volatility often associated with speculative biotechnology assets. The Beta value is 1.63, which means the stock's price volatility is 63% higher than that of the broader market, indicating that the asset is sensitive to market swings and sector-specific sentiment regarding clinical trial outcomes.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, preventing a direct comparison of growth rates between earnings and revenue. Since the company does not pay dividends, the Dividend Yield is N/A and the Payout Ratio is 0.0%, which confirms that the company reinvests all available resources, including the $29.90M cash reserve, into research and development rather than distributing income to shareholders. This reinvestment strategy is standard for pre-clinical stage immuno-oncology companies like BriaCell that must secure Phase 3 clinical trial milestones to advance their lead candidate, Bria-IMT. The overall growth and income profile is defined by the absence of current commercial earnings and a total focus on capitalizing on future potential rather than delivering immediate financial returns to investors.